The present invention relates to stable liquid oral pharmaceutical formulations of cannabidiol (CBD). The invention further discloses methods of producing a stabilized formulation of cannabidiol using cannabidiol from a synthetic source.
ABSTRACT
Inflammatory disorders of the lung are induced by COVID-19 disease, asthma, and numerous other disorders. Omega-3 fatty acids (03FA ), particularly docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) or eicosapentaenoic acid (EPA), have known anti-inflammatory and pro-resolving properties. RedĂșction of...
The present invention relates to liquid pharmaceutical formulations of bilastine and a process of preparing such formulations.these formulations are used to treat conditions caused by allergens or foreign substances.
The present invention relates to liquid pharmaceutical formulations of bilastine and a process of preparing such formulations.these formulations are used to treat conditions caused by allergens or foreign substances.
The present invention relates to pharmaceutical compositions of cannabidiol comprising less than 0.3% of THC for treating various anxiety disorders. The invention also discloses evaluation of efficacy, safety and pharmacokinetics of these compositions for treating mild to moderate anxiety disorders.
...